US feds not losing any sleep over Sanofi Ambien generic deal violations
This article was originally published in Scrip
Executive Summary
Although Sanofi, Synthon and Watson Pharmaceuticals violated federal law by failing to inform antitrust authorities about drug patent settlement deals involving Sanofi's insomnia drug Ambien CR (zolpidem tartrate), the US government said it would not take enforcement action against the firms.